Abstract: A complex salt formed from a compound of formula (I) and an alkaloid, a preparation method therefor and use thereof are provided. In particular, a complex salt formed from rupestonic acid and matrine, oxymatrine, sophocarpine and sophoridine, or a composition thereof, has potential efficacy in treating a tumor/cancer or preparing related medicaments.

Abstract: A ferrocene derivative has the formula (I), In formula (I), Z is selected from O, NH and S; R1 is selected from hydrogen, methyl and halogen; R2 is selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy and nitro; and n is an integer from 0 to 5, and R2 may be the same or different groups. The ferrocene derivative, a salt thereof, as well as a solvate thereof have anti-tumor activity, and can be used as candidate drugs or lead compounds for treating diseases such as tumor and cancer.

Abstract: A nicotinic acid derivative is represented by formula (I), and a pharmaceutically acceptable salt or solvate thereof. In formula (I), Z is selected from O, S, NR3, wherein R3 is hydrogen or C1-6 alkyl. R1 or R2 is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halogen, cyano, nitro, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, and heterocyclyloxy. Such C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, aryl, heteroaryl, and heterocyclyl may be optionally substituted with a substituent selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halogen, cyano, nitro, and aryl. These compounds or salts thereof have a strong inhibitory activity on colorectal cancer cell line HCT-116, human lung cancer cell line A549, and breast cancer cell line MCF-7.

Abstract: A nicotinic acid derivative is represented by formula (I), and a pharmaceutically acceptable salt or solvate thereof. In formula (I), Z is selected from O, S, NR3, wherein R3 is hydrogen or C1-6 alkyl. R1 or R2 is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halogen, cyano, nitro, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, and heterocyclyloxy. Such C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, aryl, heteroaryl, and heterocyclyl may be optionally substituted with a substituent selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo C1-6 alkyl, halogen, cyano, nitro, and aryl. These compounds or salts thereof have a strong inhibitory activity on colorectal cancer cell line HCT-116, human lung cancer cell line A549, and breast cancer cell line MCF-7.

Abstract: The present invention relates to the ferrocene derivative represented by formula (IA) or formula (IB), or to the pharmaceutically acceptable salt or solvate thereof and to the pharmaceutical composition thereof. Wherein, R is independently selected from H, halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, hydroxy-C1-C6 alkyl, halo-C1-C6 alkyl, halo-C1-C6 alkoxy or C1-C6 alkoxy-C1-C6 alkoxy; Z is selected from O, S or NR1, wherein R1 is independently H or C1-C6 alkyl; n is an integer from 0 to 5. The present invention also provides a method and the pharmaceutical application thereof for preparing the compounds represented by formula (IA) or formula (IB) or the pharmaceutically acceptable salts thereof. The compounds have a strong inhibitory activity against human lung cancer cell line A549, colorectal cancer cell line HCT116 and/or breast cancer cell line MCF-7.

Abstract: This disclosure provides thieno[2,3-d]pyrimidine compounds containing isoxazole heterocycle represented by formula (I), or pharmaceutically acceptable salts thereof. Such compounds are useful for the treatment of diseases including tumors and cancers.

Abstract: This invention provides a class of quinazoline compounds, as represented by formula (I), and their pharmaceutically acceptable salts, wherein: each of R1 and R2 independently, is selected from H, C1-C6 alkoxy, halo-C1-C6 alkoxy, C1-C6-alkoxy-C1-C6 alkoxy, C3-C8 cycloalkoxy, C3-C8 heterocycloalkoxy containing at least one of heteroatoms selected from N, O, S; Z is —NR4—, C(R5)2, S or —O—, wherein R4 is H or C1-C3 alkyl, R5 is the same or different, selected from H or C1-C3 alkyl; R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 alkoxy or halo-C1-C6 alkyl; n is an integer from 0 to 5. This invention also provides methods of preparation and medical uses of the compounds of formula (I) and their pharmaceutically acceptable salts. These compounds have the activity of inhibiting EGFR-TK, and can be used as drugs for the treatment of protein tyrosine kinase related diseases such as tumors, cancers, etc.

Abstract: This invention provides thieno[2,3-d]pyrimidine derivatives containing isoxazole heterocycle represented by formula (I), or pharmaceutically acceptable salts thereof Wherein: R1 and R2 may be the same or different and is independently to each other selected from H, C1-6 alkyl, C1-6 alkoxy, halo-C1-6 alkyl or halo-C1-6 alkoxy, aryl group optionally substituted by R7 or heteroaryl group optionally substituted by R8; or R1 and R2 together with the carbon atoms to which they are attached, may form a 4- to 6-membered carbocyclic ring or heterocyclic ring; said carbocyclic ring or heterocyclic ring is optionally substituted by H, C1-6 alkyl, halogen, nitro, or amino; said heterocyclic ring contains at least one heteroatom selected from N, O or S; Z is —NR6—, C(R6)2, —S— or —O—, in which R5 is H or C1-6 alkyl, and R6 is the same or different, selected from H, C1-6 alkyl or hydroxyl substituted C1-6 alkyl; R3 is selected from H, halogen, C1-6 alkyl, C1-6 alkoxy, halo-C1-6 alkyl or halo-C1-6 alkoxy; n is an inte

Abstract: This invention provides a class of quinazoline compounds, as represented by formula (I), and their pharmaceutically acceptable salts, wherein: each of R1 and R2 independently, is selected from H, C1-C6 alkoxy, halo-C1-C6 alkoxy, C1-C6-alkoxy-C1-C6 alkoxy, C3-C8 cycloalkoxy, C3-C8 heterocycloalkoxy containing at least one of heteroatoms selected from N, O, S; Z is —NR4—, C(R5)2, S or —O—, wherein R4 is H or C1-C3 alkyl, R5 is the same or different, selected from H or C1-C3 alkyl; R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 alkoxy or halo-C1-C6 alkyl; n is an integer from 0 to 5. This invention also provides methods of preparation and medical uses of the compounds of formula (I) and their pharmaceutically acceptable salts. These compounds have the activity of inhibiting EGFR-TK, and can be used as drugs for the treatment of protein tyrosine kinase related diseases such as tumours, cancers, etc.